Trials / Terminated
TerminatedNCT00479856
Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer
An Open-label, Multi-centre Study of Lapatinib in Combinationwith Chemotherapy in Patients With ErbB2 Overexpressing Breastcancer After Trastuzumab Failure in the Neoadjuvant or Adjuvantsetting.
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety and efficacy of lapatinib in combination with chemotherapy (capecitabine, docetaxel, nab-paclitaxel) in subjects with ErbB2-overexpressing breast cancer whose disease has progressed during or within 12 months after completion of trastuzumab-containing therapy in the neoadjuvant or adjuvant setting.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lapatinib | Small molecule tyrosine kinase inhibitor |
| DRUG | Capecitabine | Chemotherapy |
| DRUG | Docetaxel | Chemotherapy |
| DRUG | nab-Paclitaxel | Chemotherapy |
Timeline
- Start date
- 2007-11-01
- Primary completion
- 2009-09-01
- Completion
- 2010-03-01
- First posted
- 2007-05-28
- Last updated
- 2012-06-05
- Results posted
- 2010-06-02
Locations
28 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00479856. Inclusion in this directory is not an endorsement.